Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.

Frontiers in immunology - 1 Jan 2026

Tokat Ünal Metin, Bilgiç Şevval Nur, Adibi Ashkan, Aydın Esranur, Tutar Onur, Cansız Hilal, Altay Ali Yılmaz, Akgul Babacan Nalan, Özgü Eylül, Manea Alina Melisa, Demiray Mutlu

Abstract excerpt

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are rare malignancies characterized by resistance to chemotherapy and poor clinical outcomes. While immunotherapy have shown promise, especially in the first-line treatment, effective therapeutic strategies for patients with PD-L1-negative tumors and complex genomic profiles remain undefined. We report a case of chemorefractory SMARCA4-UT in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 6

Share to DNA Helicases

Share to Drug Resistance, Neoplasm

Share to Immunotherapy

Share to Piperazines

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 42238573
DOI: 10.3389/fimmu.2026.1858358
PMCID: PMC13226164

Genes

SMARCA4
CDK4
CDKN2A
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.PMID 42238573Read ↗

Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.Semantic proximity Read ↗

Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.Semantic proximity Read ↗

Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.Semantic proximity Read ↗

Molecular and Treatment Characteristics of SMARCB1 or SMARCA4-Deficient Undifferentiated Tumor: Retrospective Case SeriesSemantic proximity Read ↗

[Clinical characteristics and prognostic analysis of thoracic SMARCA4-deficient undifferentiated tumor].Semantic proximity Read ↗

Intestinal SMARCA4-deficient undifferentiated carcinoma: a case series and systematic review of the literature.Semantic proximity Read ↗

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.Semantic proximity Read ↗

Usefulness of BRG1 immunostaining in detecting SMARCA4 deficiency in "so-called" cancers of unknown primary in daily pathology practice.Semantic proximity Read ↗

Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4- deficent thoracic tumorsSemantic proximity Read ↗

Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer.Semantic proximity Read ↗

Establishment and characterization of TRI-LC21: a novel patient-derived cell line of SMARCA4-deficient undifferentiated thoracic tumor.Semantic proximity Read ↗

[Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.